实体器官移植、HIV或乙肝/丙肝感染患者接受抗PD-1/PD-L1免疫治疗的多中心回顾研究
移植患者6例中发生2例移植物排斥(1例死亡)、2例部分缓解;HIV感染者12例中4例缓解;乙肝和丙肝各14例中均3例缓解,病毒载量未升高且无意外毒性。
要点
- HIV或乙肝/丙肝感染患者接受抗PD-1/PD-L1治疗可能有效且不增加毒性。
- 实体器官移植患者存在移植物排斥风险,其中1例排斥导致死亡。
- 移植患者中也有2例部分缓解,需仔细权衡免疫治疗的角色。
核心结论
- HIV或乙肝/丙肝感染患者接受抗PD-1/PD-L1免疫治疗可能获得缓解,且未增加毒性或病毒载量升高。
- 实体器官移植患者存在移植物排斥风险(6例中2例排斥、1例死亡),但也有2例部分缓解,需谨慎考虑免疫治疗。
研究设计与样本
- 多中心回顾性研究,纳入16个中心的晚期癌症患者。
- 患者分组包括实体器官移植6例、HIV感染12例、乙肝14例、丙肝14例。
主要发现
- 实体器官移植患者6例中发生2例移植物排斥,其中1例导致死亡,另有2例部分缓解。
- HIV感染患者12例中有4例缓解。
- 乙肝患者14例中有3例缓解,丙肝患者14例中也有3例缓解。
- 各病毒感染组均未观察到意外毒性或病毒载量升高。
临床怎么用
- 对HIV或乙肝/丙肝感染的晚期癌症患者,可考虑使用抗PD-1/PD-L1免疫治疗,但需监测病毒载量和毒性。
- 对实体器官移植患者,使用抗PD-1/PD-L1免疫治疗前应充分评估移植物排斥风险,并权衡潜在获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anti-programmed cell death protein 1/programmed death ligand 1 (PD-1/PD-L1) immunotherapy is now routinely used to treat several cancers. Clinical trials have excluded several populations, including patients with solid organ transplant, HIV infection and hepatitis B/C infection. We examined the safety outcomes of these populations treated with anti-PD-1/PD-L1 treatment in a multicentre retrospective study. METHODS: Patients from 16 centres with advanced cancer and solid organ transplant, HIV infection or hepatitis B/C infection were included. Demographic, tumour, treatment, toxicity and outcome data were recorded. RESULTS: Forty-six patients were included for analysis, with a median age of 60 years, and the majority of patients diagnosed with melanoma (72%). Among six patients with solid organ transplants, two graft rejections occurred, with one resulting in death, whereas two patients achieved partial responses. There were four responses in 12 patients with HIV infection. In 14 patients with hepatitis B, there were three responses, and similarly, there were three responses in 14 patients with hepatitis C. There was no unexpected toxicity in any viral infection group or an increase in viral load. CONCLUSION: Patients with HIV or hepatitis B/C infections treated with anti-PD-1/PD-L1 immunotherapy may respond to treatment without increased toxicity. Given the risk of graft rejection in solid organ transplant patients and also the potential for response, the role of anti-PD-1/PD-L1 immunotherapy needs to be carefully considered.
引用
- Tio M, Rai R, Ezeoke OM, et al. Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. Eur J Cancer. 2018. PMID: 30347289. doi:10.1016/j.ejca.2018.09.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。